Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Executive Summary

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18

You may also be interested in...

Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women

Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.

Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec

As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.

Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer

Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts